Our vision is to develop a new drugs for treatment of anti-depression and addictions by using existing regulatory approved anti-depression drug formulation with Ibogaine
Ibogaine is also known to affect the brain like antidepressant drugs, but in different pathways. Thus, we believe there might be a synergy between these 2 drugs to treat depression with better efficacy and less side effects.
we believe we will be able to develop an improved anti-depression drug over the existing ones.
C.E.O. and Co-Founder
Itay is an entrepreneur with Experience in the private and public sector . itay initiated the first public trade medical Cannabis company in Tel Aviv Stock Exchange. Itay is an experienced manager, served as the CEO of Hi-Pharma ltd a medical cannabis company for 2 years ,and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation. itay holds a degree in Water & Soil Engineering from the Rupin Academic Center, and a B.A. in Geography and Environment from the Haifa University, Israel.
chairman and co-founder
Asher has over 30 years' experience in management of both private and public corporations in the medical device and the biotech industry. His expertise covers a wide range of activities including product development, clinical studies, regulatory affairs and marketing. Asher founded several successful bio-tech companies, served as their chairman and president among them InspireMD (NYSE MKT: NSPR), a medical device company which improves treatment of patients undergo stenting related to heart attacks; UroGen Pharma (NASDAQ: URGN)FDA approved drug for urological pathologies. Asher Holzer was part of the management team of Biosense which was acquired by Johnson & Johnson in 1997 and become the worldwide market leader in developing and marketing products for the diagnosis and treatment of cardiac arrhythmias. Asher holds a Ph.D. in Applied Physics and a M.Sc. in Material Science from Hebrew University in Jerusalem, Israel. He holds several granted and pending patents, mainly in the fields of interventional cardiology and urology.
CTO and Co- founder
kobi is an entrepreneur and founder of CANNADORF LTD, with over 10 years of academic and industrial research and managing experience, in multidisciplinary areas in the field of microbiology, molecular biology, plant sciences, diagnostics, and medical devices. He also possesses an extended background in regulation, business development and the vision to leverage his background in science into successful commercial products. Kobi holds a B.Sc. in Horticulture and Plant Protection (Summa Cum Laude) an M.Sc. in plant genetics and breeding (Summa Cum Laude) both from The Hebrew University of Jerusalem, an M.A. in Business Administration from the College of Management, and a Ph.D. from the Hebrew University of Jerusalem.
Noam has over 15 years of academic experience in the field of neuroscience and over 10 years of industrial experience at a medical device company (BrainsWay Ltd.) that target psychiatric conditions. He planned and managed both preclinical and clinical experiments and has vast experience in the a priori scientific literature reviews, in analyzing and interpreting results, and in their communication to different audiences. Noam hold a B. Tech in Biotechnology Engineering from the Ort Braude College, an M.Sc. in Life Sciences from the Bar-Ilan University (in cooperation with the Weizmann institute), and a Ph.D from the Ben-Gurion University.
Dr Jeremy Weate is an authority on psychedelic-assisted psychotherapy. He joined the board of Vancouver-based Universal Ibogaine in February 2020 and from June 2020 to March 2021 he was CEO. He has organized conferences on ibogaine in Vienna, Porto and London and co-founded. Tabula Rasa Retreat in Portugal in 2018 He has twenty years’ experience leading over sixty team-based projects advising governments. around the world in the mining sector, from Armenia to Zambia. He has a PhD in philosophy from Warwick University and is the author of a best-selling book on philosophy for children. Chief Executive Officer – Universal Ibogaine June 2020-February 2021 Developed a new business strategy for the company in June which led to a successful $8m private placement raise, listed as one of the top psychedelic companies by Business Insider in February 2021. Grew the team and set up key operational processes and accountabilities to ensure a tightly goal-oriented and efficient organization, well set to go public in 2021 on the TSX and complete a clinical trial application for ibogaine for opioid use disorder, also in 2021.
Head of Agricultural Research
Dr. Maggie Levy holds a Ph.D. and M. Sc. in Plant Sciences and B.Sc. in Horticulture and Plant Protection from the Robert H. Smith Faculty of Agriculture, Food and Environment, the Hebrew University of Jerusalem. Since 2006, Maggie is a head of a laboratory in the Department of Plant Pathology and Microbiology at the Hebrew University of Jerusalem. The research activities in Maggie’s lab are multilayered and combined of basic and applicative research that focus on plant-pathogen interactions and plant immunity. She is also an expert in plant secondary metabolites and studies their impact on fungal pathogens. To date, Dr. Levy has granted highly competitive research grants, supervised M.Sc. and Ph.D. students and postdoctoral fellows and published an impressive number of articles in top, peer-reviewed, professional journals.